Monopar Therapeutics
For the period ended Dec 31, 2025. Filed Mar 27, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 27, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 15. Exhibits, Financial Statement Schedule
1. Financial Statements
INDEX TO FINANCIAL STATEMENTS
| Page | |
| Report of Independent Registered Public Accounting Firm (PCAOB ID: 207) | F-2 |
|---|---|
| Consolidated Balance Sheets as of December 31, 2025 and 2024 | F-3 |
| Consolidated Statements of Operations and Comprehensive Loss for the Years Ended December 31, 2025 and 2024 | F-4 |
| Consolidated Statements of Stockholders’ Equity for the Years Ended December 31, 2025 and 2024 | F-5 |
| Consolidated Statements of Cash Flows for the Years Ended December 31, 2025 and 2024 | F-6 |
| Notes to Consolidated Financial Statements | F-7 to F-23 |
2. Financial Statements Schedules
Other financial statements schedules are not included because they are not required, or the information is otherwise shown in the Consolidated Financial Statements or notes thereto.
(b) Exhibits
The following exhibits are filed as part of this Annual Report on Form 10-K.
| Exhibit | Document | Incorporated by Reference From: |
| 3.2 | Certificate of Amendment to the Second Amended and Restated Certificate of Incorporation | Form 8-K filed on August 9, 2024 |
| 3.3 | Amended and Restated Bylaws | Form 10-Q filed on May 12, 2022 |
| 4.1 | Description of Registered Securities | Filed herewith as Exhibit 4.1 |
| 4.2 | Form of Pre-funded Warrant | Form 8-K filed on December 23,2024 |
| 10.5 | Employment Agreement of Chandler D. Robinson – effective November 1, 2017 | Form 10-K filed on March 26, 2018 |
| 10.6 | Consulting Agreement of pRx Consulting (Patrice Rioux) – effective January 1, 2026 | Filed herewith as Exhibit 10.6 |
| 10.7 | Consulting Agreement of Christopher M. Starr – effective January 1, 2022 | Form 10-K filed on March 24, 2022 |
| 10.8* | License Agreement with Alexion Pharmaceuticals, Inc. | Form 8-K filed on October 24, 2024 |
| 10.9 | Common Stock Investment Agreement with Alexion Pharmaceuticals, Inc. | Form 8-K filed on October 24, 2024 |
| 10.10 | Securities Purchase Agreement | Form 8-K filed on October 30, 2024 |
| 10.11 | Securities Purchase Agreement | Form 8-K filed on December 23, 2024 |
| 10.12 | Registration Rights Agreement | Form 8-K filed on December 23, 2024 |
| 10.15 | Share Purchase Agreement with Tactic Pharma, LLC | Form 8-K filed on September 24, 2025 |
| 10.16 | Employment Agreement with Susan Rodriguez – effective March 2, 2026 | Filed herewith as Exhibit 10.16 |
| 19.1 | Insider Trading Policy | Filed herewith as Exhibit 19.1 |
| 21.1 | Subsidiaries of Monopar Therapeutics Inc. as of December 31, 2025 | Filed herewith as Exhibit 21.1 |
| 23.1 | Consent of BPM LLP, Independent Registered Public Accounting Firm | Filed herewith as Exhibit 23.1 |
| 24.1 | Power of Attorney (included in the signature page hereto) | |
| 31.1 | Certification of Chandler D. Robinson, Chief Executive Officer | Filed herewith as Exhibit 31.1 |
| 31.2 | Certification of Quan Vu, Chief Financial Officer | Filed herewith as Exhibit 31.2 |
| 32.1 | Certification of Chandler D. Robinson, Chief Executive Officer and Quan Vu, Chief Financial Officer | Filed herewith as Exhibit 32.1 |
| 101.INS | Inline XBRL Taxonomy Extension Schema |
| 101.SCH | Inline XBRL Taxonomy Extension Schema |
| 101.CAL | Inline XBRL Taxonomy Extension Calculation Linkbase |
| 101.DEF | Inline XBRL Taxonomy Extension Definition Linkbase |
| 101.LAB | Inline XBRL Taxonomy Extension Label Linkbase |
| 101.PRE | Inline XBRL Taxonomy Extension Presentation Linkbase |
| 104 | Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101) |
Confidential Information has been omitted and filed separately with the SEC on exhibits marked with (*).
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| MONOPAR THERAPEUTICS INC | ||
| Dated: March 27, 2026 | By: | /s/ Quan Vu |
|---|---|---|
| Name: Quan Vu | ||
| Title: Chief Financial Officer | ||
| (Principal Financial Officer) | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.